ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy

Diabetes

Volumn 62, Issue 10, 2013, Pages 3599-3609

  Rurali, Erica ^a   Noris, Marina ^a   Chianca, Antonietta ^a   Donadelli, Roberta ^a   Banterla, Federica ^a   Galbusera, Miriam ^a   Gherardi, Giulia ^a   Gastoldi, Sara ^a   Parvanova, Aneliya ^a   Iliev, Ilian ^a   Bossi, Antonio ^b   Haefliger, Carolina ^c   Trevisan, Roberto ^d   Remuzzi, Giuseppe ^a,d   Ruggenenti, Piero ^a,d  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Treviglio Hospital   (Italy)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; ALANINE; BIOLOGICAL MARKER; PROLINE; VON WILLEBRAND FACTOR;

ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC PATIENT; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME POLYMORPHISM; FEMALE; GENOTYPE; HOMOZYGOTE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; BLOOD; CHRONIC KIDNEY FAILURE; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DISEASE COURSE; GENETICS; MIDDLE AGED; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES;

ADAM PROTEINS; AGED; ALANINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GENOTYPE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROLINE; PROTEOLYSIS; RISK ASSESSMENT; RISK FACTORS; VON WILLEBRAND FACTOR;

EID: 84891501581     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-0530     Document Type: Article

References (50)

1. Schramm TK, Gislason GH, Køber L, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008;117:1945-1954
2. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-232
3. Ruggenenti P, Fassi A, Ilieva AP, et al.; BENEDICT-B Study Investigators. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. J Hypertens 2011;29:207-216
4. Ruggenenti P, Fassi A, Ilieva AP, et al.; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-1951
5. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345: 861-869
6. Investigators TH; Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259
7. Mustand JF, Packham MA. Platelets and diabetes mellitus. N Engl J Med 1984;311:665-667
8. Yu Y, Suo L, Yu H, Wang C, Tang H. Insulin resistance and endothelial dysfunction in type 2 diabetes patients with or without microalbuminuria. Diabetes Res Clin Pract 2004;65:95-104
9. Meigs JB, O'Donnell CJ, Tofler GH, et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes 2006;55:530-537
10. Kistorp C, Chong AY, Gustafsson F, et al. Biomarkers of endothelial dysfunction are elevated and related to prognosis in chronic heart failure patients with diabetes but not in those without diabetes. Eur J Heart Fail 2008;10:380-387
11. Sporn LA, Marder VJ, Wagner DD. von Willebrand factor released from Weibel-Palade bodies binds more avidly to extracellular matrix than that secreted constitutively. Blood 1987;69:1531-1534
12. Turner NA, Nolasco L, Ruggeri ZM, Moake JL. Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage. Blood 2009;114: 5102-5111
13. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002;100:4033-4039
14. Galbusera M, Noris M, Remuzzi G. Inherited thrombotic thrombocytopenic purpura. Haematologica 2009;94:166-170
15. Lemkes BA, Hermanides J, Devries JH, Holleman F, Meijers JC, Hoekstra JB. Hyperglycemia: a prothrombotic factor? J Thromb Haemost 2010;8: 1663-1669
16. Vazzana N, Ranalli P, Cuccurullo C, Davì G. Diabetes mellitus and thrombosis. Thromb Res 2012;129:371-377
17. Hirano T, Ookubo K, Kashiwazaki K, Tajima H, Yoshino G, Adachi M. Vascular endothelial markers, von Willebrand factor and thrombomodulin index, are specifically elevated in type 2 diabetic patients with nephropathy: comparison of primary renal disease. Clin Chim Acta 2000; 299:65-75
18. Fioretto P, Stehouwer CD, Mauer M, et al. Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure. Diabetologia 1998;41:233-236
19. Persson F, Rossing P, Hovind P, et al. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. Scand J Clin Lab Invest 2008;68:731-738
20. Frankel DS, Meigs JB, Massaro JM, et al. Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the Framingham Offspring study. Circulation 2008;118:2533-2539
21. Pelras S, Delmas Y, Lamireau D, et al. Severe transient ADAMTS13 deficiency in pneumococcal-associated hemolytic uremic syndrome. Pediatr Nephrol 2011;26:631-635
22. Zhao BQ, Chauhan AK, Canault M, et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood 2009;114:3329-3334
23. Gandhi C, Motto DG, Jensen M, Lentz SR, Chauhan AK. ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/ reperfusion injury in mice. Blood 2012;120:5224-5230
24. Doi M, Matsui H, Takeda H, et al. ADAMTS13 safeguards the myocardium in a mouse model of acute myocardial infarction. Thromb Haemost 2012; 108:1236-1238
25. Taniguchi S, Hashiguchi T, Ono T, et al. Association between reduced ADAMTS13 and diabetic nephropathy. Thromb Res 2010;125:e310-e316
26. Kaikita K, Soejima K, Matsukawa M, Nakagaki T, Ogawa H. Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost 2006;4:2490-2493
27. Chion CK, Doggen CJ, Crawley JT, Lane DA, Rosendaal FR. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood 2007;109:1998-2000
28. Kokame K, Matsumoto M, Soejima K, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 2002;99:11902-11907
29. Plaimauer B, Fuhrmann J, Mohr G, et al. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood 2006;107:118-125
30. Jang MJ, Kim NK, Chong SY, et al. Frequency of Pro475Ser polymorphism of ADAMTS13 gene and its association with ADAMTS-13 activity in the Korean population. Yonsei Med J 2008;49:405-408
31. De Cosmo S, Motterlini N, Prudente S, et al.; BENEDICT Study Group. Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT. Diabetes 2009;58:2920-2929
32. Maeda S, Kobayashi MA, Araki S, et al. A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes. PLoS Genet 2010;6:e1000842
33. Kathiresan S, Melander O, Anevski D, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008;358: 1240-1249
34. Krolewski AS, Poznik GD, Placha G, et al. A genome-wide linkage scan for genes controlling variation in urinary albumin excretion in type II diabetes. Kidney Int 2006;69:129-136
35. BENEDICT Group. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics. Control Clin Trials 2003;24:442-461
36. Noris M, Bucchioni S, Galbusera M, et al.; International Registry of Recurrent and Familial HUS/TTP. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol 2005;16:1177-1183
37. Galbusera M, Bresin E, Noris M, et al. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood 2005;106:925-928
38. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med 1993;118:201-210
39. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326:219
40. Bellera CA, MacGrogan G, Debled M, de Lara CT, Brouste V, Mathoulin- Pélissier S. Variables with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic factor study in breast cancer. BMC Med Res Methodol 2010;10:20
41. Lancellotti S, De Filippis V, Pozzi N, et al. Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. Free Radic Biol Med 2010;48:446-456
42. Okumura M, Imanishi M, Okamura M, et al. Role for thromboxane A2 from glomerular thrombi in nephropathy with type 2 diabetic rats. Life Sci 2003; 72:2695-2705
43. Khajehdehi P, Roozbeh J, Mostafavi H. A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scand J Urol Nephrol 2002;36:145-148
44. De Meyer SF, Savchenko AS, Haas MS, et al. Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice. Blood 2012;120:5217-5223
45. Hershon KS. Mechanistic and clinical aspects of renin- angiotensinaldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease. Endocr Pract 2011;17:430-440
46. Napoli C, Bruzzese G, Ignarro LJ, et al. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intimamedia thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J 2008;156:1154.e1151-1158
47. Bravi MC, Armiento A, Laurenti O, et al. Insulin decreases intracellular oxidative stress in patients with type 2 diabetes mellitus. Metabolism 2006; 55:691-695
48. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996;19:257-267
49. Hernández E, Toledo T, Alamo C, Mon C, Rodicio JL, Praga M. Elevation of von Willebrand factor levels in patients with IgA nephropathy: effect of ACE inhibition. Am J Kidney Dis 1997;30:397-403
50. Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 2001;103:1746-1751